LOGOLOGOLOGOLOGO
    • About us
      • What we do
      • Who we are
        • Governance
        • Staff
        • Vacancies
    • Members
      • EuropaBio Members
      • About Membership
    • How we work
      • Healthcare Biotechnology Council
        • Patient BioForum
        • Study – Impact of the EU’s General Pharmaceutical Legislation
      • Industrial Biotechnology Council
        • EFIB
        • Microorganisms
      • National Associations Council
      • SME Platform
      • Biomanufacturing Platform
        • Biotechnology in our Lives
    • Activities
      • 25 Years of Innovation
      • The EU Biotech Act
      • European Biotech Week
      • EU Projects
        • PRIMED Project
        • APROVALS Project
    • News & Events
      • News
      • Events
    • Library
    Become a member
    ✕

    Lacidofil®: The Original Formula for A Resilient Gut Microbiome

    15/12/2025

    CASE STUDY

    Submission from Lallemand

    It all starts in the gut with our proprietary probiotic solutions! With over 160 publications (including preclinical and clinical studies) Lallemand Health Solutions’ thoroughly documented bacteria and yeast strains provide beneficial health effects such as on gut microbiota balance and or incidence of diarrhea and constipation. They also support the intestinal flora of specific populations, such as infants during their first year of life and adults with certain gut health conditions.

    The innovation.

    Lacidofil®: Recent Study Reveals Promising Results for H. pylori Eradication

    Among our most documented solutions is the probiotic formula, Lacidofil®, which combines two proprietary bacterial strains: L. rhamnosus Rosell®-11 and L. helveticus Rosell®-52. Supported by over 29 clinical trials, Lacidofil® has consistently shown its beneficial effects on maintaining healthy intestinal microbiota, leading to overall well-being in humans. A recent study [Kiattiweerasak, 2023] strengthens existing evidence that Lacidofil® is an effective adjuvant to standard therapy for Helicobacter pylori (H. pylori) eradication and reduces the side effects of antibiotics used in this therapy.

    The benefits.

    Lacidofil® decreases gastrointestinal discomfort and improves general health-related quality of life

    The results demonstrate the efficacy and safety of Lacidofil® in statistically significantly increasing gastrointestinal comfort whilst improving general health-related quality of life at week six compared to the placebo group. The study also highlights that Lacidofil® can significantly increase the eradication rate of H. pylori.

    Lacidofil® is available in over 20 countries, both as a standalone product and as an ingredient in combination with other strains. With a proven record of safe use and a robust pharmacovigilance program, Lacidofil® has earned Canadian approval for various health claims. These include promoting healthy microflora in infants as young as two months old, addressing Antibiotic-Associated Diarrhea (AAD), management of acute diarrhea, support of gastrointestinal balance during H. pylori eradication therapy, as well as offering non- specific general well-being benefits to pregnant women.

    Lacidofil® is available in various forms, including powders, capsules, and drops, a versatility that meets current market probiotic solution demand.

    Additional materials:

    Visit our dedicated website to learn more

     

    Lacidofil®: The Original Formula for A Resilient Gut Microbiome


    Download

    Share
    Adrian Lincoln
    Adrian Lincoln

    Related posts

    18/05/2026

    Biodefence & Biosecurity in focus for EuropaBio with dedicated Task Force


    Read more
    12/05/2026

    ‘Consistency, cooperation and practicality are the watch words’. EuropaBio reacts to provisional agreement on the Critical Medicines Act


    Read more
    08/05/2026

    Technovative Solutions Ltd. joins EuropaBio: Advancing AI‑Driven and Sustainable Innovation in Biotechnology


    Read more

    Important links

    • Biodefence & Biosecurity in focus for EuropaBio with dedicated Task Force
    • ‘Consistency, cooperation and practicality are the watch words’. EuropaBio reacts to provisional agreement on the Critical Medicines Act

    Categories in our Newsroom

    EBIO-white

    EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

    Contact us

    Extra links

    Members
    Staff
    Privacy policy
    Legal & cookies
    Events
    Newsroom

    Become a member

    Media pack

    © 2026 Europabio. All Rights Reserved. Designed by EYAS
    Become a member

    Vitamin B2

    The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

    Insulin

    Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.

    Detergents

    Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

    Clothes

    Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

    Algal Omega 3

    Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

    Cheese

    Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.